Abstract: A preservative-free, sterile packaged ophthalmic device product is disclosed. The preservative-free, sterile packaged ophthalmic device product is obtained by (a) adding at least one polyquaternium polymer to an aqueous packaging solution for preventing antimicrobial contamination during storage; (b) packaging the aqueous packaging solution and an ophthalmic device in a manner preventing contamination of the ophthalmic device by one or more microorganisms; and (c) heat sterilizing the aqueous packaging solution and the ophthalmic device, whereby the at least one polyquaternium polymer decomposes during the heat sterilizing to obtain the preservative-free packaged ophthalmic device product.

Abstract: Sterilized aqueous solution comprising 0.04% to 0.8% by weight hyaluronic acid with a weight average molecular weight from 0.6 MDa to 3.6 MDa, and one or more buffer components selected from the group consisting of boric acid, sodium borate and sodium dihydrogen phosphate. The aqueous solution also has an ionic strength equivalent to an aqueous concentration of sodium chloride from 4% to 18% by weight of sodium chloride and a pH from 6.4 to 7.2. The solution is also filtered through a filter medium that has an average pore size of 0.25 ?m or less to provide a sterilized high salt, hyaluronic acid solution.

Abstract: Sterilized aqueous solution comprising 0.04% to 0.8% by weight hyaluronic acid with a weight average molecular weight from 0.6 MDa to 3.6 MDa, and one or more buffer components selected from the group consisting of boric acid, sodium borate and sodium dihydrogen phosphate. The aqueous solution also has an ionic strength equivalent to an aqueous concentration of sodium chloride from 4% to 18% by weight of sodium chloride and a pH from 6.4 to 7.2. The solution is also filtered through a filter medium that has an average pore size of 0.25 ?m or less to provide a sterilized high salt, hyaluronic acid solution.

Abstract: A process for sterilizing a solution comprising hyaluronic acid. The process comprises providing an aqueous solution of hyaluronic acid with a weight average molecular weight from 0.6 MDa to 3.6 MDa, and the concentration of the hyaluronic acid is from 0.04% to 0.8% by weight. The aqueous solution also has an ionic strength equivalent to an aqueous concentration of sodium chloride from 3% to 30% by weight. Once the aqueous, high salt, hyaluronic acid solution is prepared the solution is maintained at a temperature from 40° C. to 80° C. for at least 1 hour and not longer than six days. Following the heat treatment step, the aqueous solution is filtered through a sterilization filter medium to provide a sterilized high salt, hyaluronic acid solution.

Abstract: A process for sterilizing a solution comprising hyaluronic acid. The process comprises providing an aqueous solution of hyaluronic acid with a weight average molecular weight from 0.6 MDa to 3.6 MDa, and the concentration of the hyaluronic acid is from 0.04% to 0.8% by weight. The aqueous solution also has an ionic strength equivalent to an aqueous concentration of sodium chloride from 3% to 30% by weight. Once the aqueous, high salt, hyaluronic acid solution is prepared the solution is maintained at a temperature from 40° C. to 80° C. for at least 1 hour and not longer than six days. Following the heat treatment step, the aqueous solution is filtered through a sterilization filter medium to provide a sterilized high salt, hyaluronic acid solution.

Abstract: A polymeric biguanide composition comprising less than 18 mol % of terminal amine groups as measured by 13C NMR. The polymeric biguanide composition also is characterized by a relative increase in the molar concentration of terminal guanidine groups or terminal cyanoguanidino groups. The invention is also directed to ophthalmic compositions comprising the polymeric biguanide compositions. The polymeric biguanide compositions can be used as an antimicrobial component in an ophthalmic lens care solution, or as a preservative to in a pharmaceutical composition or other health care product.

Abstract: A contact lens care solution comprising: a cationic antimicrobial component having an average molecular weight (MNA), and a cationic oligomer or nitrogen/amine oligomer having a number average molecular weight (MNO) from 500 daltons to 15,000 daltons. The lens care solutions are used to clean and disinfect contact lenses, and in particular, soft, silicone hydrogel contact lenses.

Abstract: An ophthalmic composition comprising a polymeric biguanide composition having less than 18 mol % of terminal amine groups and 55 mol % or greater of terminal guanidine groups as measured by 13C NMR, and 0.005 w/v % to 0.04 w/v % hyaluronic acid. Alternatively, the ophthalmic composition comprises a polymeric biguanide composition comprising less than 18 mol % of terminal amine groups and 40 mol % or greater of terminal cyanoguanidino groups as measured by 13C NMR, and 0.005 w/v % to 0.04 w/v % hyaluronic acid. The compositions can be used for cleaning, disinfecting or packaging a contact lens.

Abstract: A polymeric biguanide composition comprising less than 18 mol % of terminal amine groups as measured by 13C NMR. The polymeric biguanide composition also is characterized by a relative increase in the molar concentration of terminal guanidine groups or terminal cyanoguanidino groups. The invention is also directed to ophthalmic compositions comprising the polymeric biguanide compositions. The polymeric biguanide compositions can be used as an antimicrobial component in an ophthalmic lens care solution, or as a preservative to in a pharmaceutical composition or other health care product.

Abstract: A method of making a disinfecting solution that is effective at disinfecting contact lenses. The method includes the step of combining water, one or more antimicrobial agents and a reduced amount of solid content into a dissolved liquid mixture. The process results in an improved disinfection efficacy compared to a reference solution.

Abstract: An ophthalmic treatment system comprises an ophthalmic treatment solution and a biguanide antimicrobial agent in solid form and in contact with said treatment solution such as to inhibit bacterial and/or fungal growth in said solution. The biguanide is partially or wholly terminated with an amine compound.

Abstract: The present invention provides an optically clear, hydrophilic coating upon the surface of a non-plasma treated hydrophobic hydrogel lens by heating the lens in an aqueous solution containing a surface-protective agent. Alternately, the non-plasma treated hydrophobic hydrogel lens may be subjected to ultrasonication while immersed in an aqueous solution containing a surface-protective agent.

Abstract: The present invention is directed to a method of treating dry eye by instilling eyedrops of a composition containing a cationic cellulosic polymer. Such compositions have been found to alleviate the symptoms of dry eye without requiring the presence of anionic therapeutic agents. Low ionic strength solutions are particularly preferred.

Abstract: The present invention provides an optically clear, hydrophilic coating upon the surface of a silicone hydrogel lens by plasma treating the lens and subsequently heating the lens in an aqueous solution containing a surface-protective agent.

Abstract: The invention is directed to compositions and methods used as in-the-eye and/or out-of-eye inhibitors of proteinaceous deposits on hydrophilic contact lenses. Compositions of the present invention comprise moderately charged polyquaternium polymers that selectively bind to hydrophilic contact lenses to block the binding of proteinaceous materials. Compositions of the present invention may be used in multipurpose cleaning solutions for contact lenses and can eliminate the need for special enzyme cleaners and the like for removing proteinaceous materials.

Abstract: The present invention is directed to a biguanide-containing disinfecting solution containing a particular type of poloxamine for stabilizing a polymeric biguanide. The poloxamine surfactant comprises at least about 90 weight percent of poly(oxyethylene) and poly(oxypropylene) segments, in one or more copolymer chains, wherein the weight average molecular weight of said surfactant is from about 10,000 to about 30,000 and wherein at least about 70 weight percent of said poly(oxyethylene) and poly(oxypropylene) segments are poly(oxyethylene) segments, and wherein the HLB value is at least 27. The method of the present invention comprises cleaning and disinfecting a contact lens with the above-described solution. Products according to the present invention provide enhanced cleaning while maintaining biocidal efficacy.

Abstract: The present invention is directed to an ophthalmically safe disinfecting solution for contact lenses comprising the combination of a polymeric biguanide and a polyquaternium polymer of a substituted or unsubstituted vinylimidazole or its vinylimidazoliuum salt, which copolymer has a weight average molecular weight of 5,000 to 5,000,000. The invention is also directed to an improved method of disinfecting a contact lens.

Abstract: The invention is directed to compositions and methods used as in-the-eye and/or out-of-eye inhibitors of proteinaceous deposits on hydrophilic contact lenses. Compositions of the present invention comprise moderately charged polyquaternium polymers that selectively bind to hydrophilic contact lenses to block the binding of proteinaceous materials. Compositions of the present invention may be used in multipurpose cleaning solutions for contact lenses and can eliminate the need for special enzyme cleaners and the like for removing proteinaceous materials.

Abstract: A method and system for disinfecting contact lenses with iodine using a neutralizing solution having a first, rapid neutralizing component which completes its reaction with available iodine in less than five seconds and a second, slower neutralizing component which completes its reaction with available iodine in about 3 to 30 minutes.

Abstract: The present invention provides non-oxidative methods for treating contact lenses and compositions for the same. The present invention includes contacting a lens with an aqueous solution comprising a phosphonic acid compound. In preferred embodiments of the invention, the subject phosphonic compounds are used in combination with antimicrobial agents for providing simultaneous disinfection and cleaning of contact lenses including the prevention or removal of protein deposits.